What is the treatment for Grover disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Grover Disease

Medium to high-potency topical corticosteroids are the first-line treatment for Grover disease, applied to affected areas 1-2 times daily for 1-4 weeks with gradual tapering. 1

Clinical Overview

Grover disease (transient acantholytic dermatosis) is a benign papulovesicular eruption that typically affects the trunk and proximal extremities. It commonly presents in middle-aged men with a male-to-female ratio of approximately 4:1, with a mean age of 59 years 2. The condition is characterized by pruritic papules and vesicle-papules that can cause significant discomfort.

Treatment Algorithm

First-Line Therapy:

  • Topical corticosteroids: Medium to high-potency formulations (e.g., triamcinolone acetonide 0.1%, clobetasol propionate) 1, 3
    • Apply 1-2 times daily to affected areas
    • Treatment duration: 1-4 weeks with gradual tapering
    • Response rate: approximately 70% 2
  • Topical vitamin D analogues can be used alongside corticosteroids 3
  • Topical menthol preparations provide counter-irritant effect for symptomatic relief 1
  • Antihistamines for adjunctive relief of pruritus 1, 3
    • Non-sedating options: fexofenadine 180mg, loratadine 10mg
    • Mildly sedating: cetirizine 10mg

Second-Line Therapy (for refractory cases):

  • Systemic retinoids (response rate: 86%) 2
    • Acitretin at 0.8mg/kg/day has shown complete remission in persistent cases 4
  • Systemic corticosteroids (response rate: 64%) 2
  • Gabapentin or pregabalin when topical treatments are insufficient 1
    • Pregabalin has shown success in treatment-resistant cases

Third-Line Therapy:

  • Phototherapy (UVB) may be beneficial, particularly when solar exposure is a known trigger 1, 3

Important Clinical Considerations

Disease Course

  • Spontaneous resolution within one week to eight months occurs in approximately 42% of cases 2
  • Some cases may follow a chronic and fluctuating course lasting several years 3

Triggering Factors to Address

  • Heat and sweating
  • Cool and dry air
  • Occlusive environments (e.g., bandages, prolonged bed rest) 5
  • Renal failure
  • Malignancy (including hematologic malignancies) 6
  • Certain medications

Common Pitfalls to Avoid

  • Inadequate treatment duration
  • Using monotherapy when combination therapy may be more effective 1
  • Failing to address underlying triggers
  • Overlooking potential associations with malignancy or other systemic conditions 6

Special Considerations

  • For localized or unilateral presentations, consider the possibility of other acantholytic dermatoses in the differential diagnosis 5
  • Combination therapy (topical treatments plus systemic medications) is often more effective than monotherapy alone 1
  • Inspect for other pathologic processes to rule out concomitant disorders 6

By following this treatment algorithm and addressing potential triggers, most patients with Grover disease can achieve symptomatic relief and disease resolution.

References

Guideline

Somatosensory Hypersensitivity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clinical features and treatments of transient acantholytic dermatosis (Grover's disease): a systematic review.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2020

Research

Grover disease: review of subtypes with a focus on management options.

International journal of dermatology, 2020

Research

Monolateral Grover's Disease with Blaschkoid Distribution.

Acta dermatovenerologica Croatica : ADC, 2017

Research

Grover disease (transient acantholytic dermatosis).

Archives of pathology & laboratory medicine, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.